Effect of fezolinetant on moderate-to-severe vasomotor symptoms in subgroups based on hormone therapy history: pooled data from two randomized phase 3 studies

被引：0
|
作者：
Santoro, Nanette [1 ]
Neal-Perry, Genevieve [2 ]
Stute, Petra [3 ]
Blogg, Martin [4 ]
Mancuso, Shayna [5 ]
Morga, Antonia [4 ]
Ottery, Faith D. [5 ]
Siddiqui, Emad [4 ]
机构：
[1] Univ Colorado, Sch Med, Aurora, CO USA
[2] UNC Sch Med, Chapel Hill, NC USA
[3] Inselspital Bern, Bern, Switzerland
[4] Astellas Pharma Europe Ltd, Addlestone, Surrey, England
[5] Astellas Pharma Global Dev Inc, Northbrook, IL USA
来源：
MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY | 2023年 / 30卷 / 12期
关键词：
D O I：
暂无
中图分类号：
R71 [妇产科学];
学科分类号：
100211 ;
摘要：
S-8
引用
收藏
页码：1259 / 1259
页数：1
相关论文
共 50 条
  • [1] Effect of fezolinetant on moderate-to-severe vasomotor symptoms according to time of day: pooled data from two randomized phase 3 studies
    Neal-Perry, Genevieve
    Shapiro, Marla
    Thurston, Rebecca C.
    Wolfman, Wendy
    Blogg, Martin
    King, Deanna
    Morga, Antonia
    Ottery, Faith D.
    Siddiqui, Emad
    MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY, 2023, 30 (12): : 1287 - 1288
  • [2] Early response with fezolinetant treatment of moderate-to-severe vasomotor symptoms associated with menopause: pooled data from two randomized Phase 3 studies
    Shapiro, C. M. Marla
    Neal-Perry, Genevieve
    Stute, Petra
    Thurston, Rebecca C.
    Wolfman, Wendy
    English, Marci
    Zhao, Jun
    Ottery, Faith D.
    MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY, 2022, 29 (12): : 1483 - 1484
  • [3] Treating moderate-to-severe menopausal vasomotor symptoms with fezolinetant: analysis of responders using pooled data from two phase 3 studies (SKYLIGHT 1 and 2)
    Nappi, Rossella E.
    Johnson, Kimball A.
    Stute, Petra
    Blogg, Martin
    English, Marci
    Morga, Antonia
    Scrine, Ludmila
    Siddiqui, Emad
    Ottery, Faith D.
    MENOPAUSE-THE JOURNAL OF THE MENOPAUSE SOCIETY, 2024, 31 (06): : 512 - 521
  • [4] Fezolinetant for treatment of moderate-to-severe vasomotor symptoms associated with menopause: efficacy in women stratified by race using pooled data from two Phase 3 studies
    Neal-Perry, Genevieve
    Stute, Petra
    English, Marci
    King, Deanna
    Lee, Misun
    Morga, Antonia
    Siddiqui, Emad
    Ottery, Faith D.
    MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY, 2022, 29 (12): : 1477 - 1478
  • [5] Effect of fezolinetant treatment on patient-reported sleep disturbance: pooled data from two Phase 3 studies in women with moderate-to-severe vasomotor symptoms associated with menopause
    Marla Shapiro, C. M.
    Cano, Antonio
    Nappi, Rossella E.
    Santoro, Nanette F.
    English, Marci
    Mancuso, Shayna
    Morga, Antonia
    Siddiqui, Emad
    Valluri, Udaya
    Ottery, Faith D.
    MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY, 2022, 29 (12): : 1484 - 1484
  • [6] Fezolinetant Treatment of Moderate-to-Severe Vasomotor Symptoms Associated With Menopause: Effect of Intrinsic and Extrinsic Factors in Two Phase 3 Studies
    Santoro, Nanette
    King, Deanna
    Nappi, Rossella
    Neal-Perry, Genevieve
    Ottery, Faith
    Yamaguchi, Yusuke
    OBSTETRICS AND GYNECOLOGY, 2023, 141 : 12S - 12S
  • [7] Safety of Fezolinetant for Treatment of Moderate to Severe Vasomotor Symptoms Due to Menopause: Pooled Analysis of Three Randomized Phase 3 Studies
    Kagan, Risa
    Cano, Antonio
    Nappi, Rossella E.
    English, Marci L.
    Mancuso, Shayna
    Wu, Xi
    Ottery, Faith D.
    ADVANCES IN THERAPY, 2025, 42 (02) : 1147 - 1164
  • [8] Phase 3 Study of Fezolinetant for Treatment of Moderate-to-Severe Vasomotor Symptoms Associated With Menopause
    Lederman, Samuel
    Shapiro, Marla
    Stute, Petra
    Lee, Misun
    Wang, Xuegong
    Neal-Perry, Genevieve
    OBSTETRICS AND GYNECOLOGY, 2022, 139 : 39S - 39S
  • [9] In menopause-related moderate-to-severe vasomotor symptoms not suitable for hormone therapy, fezolinetant safely improved symptoms
    Cheung, Angela M.
    ANNALS OF INTERNAL MEDICINE, 2025,
  • [10] Fezolinetant treatment of moderate-to-severe vasomotor symptoms due to menopause: effect of intrinsic and extrinsic factors in two phase 3 studies (SKYLIGHT 1 and 2)
    Santoro, Nanette
    Nappi, Rossella E.
    Neal-Perry, Genevieve
    English, Marci
    King, Deanna D.
    Yamaguchi, Yusuke
    Ottery, Faith D.
    MENOPAUSE-THE JOURNAL OF THE MENOPAUSE SOCIETY, 2024, 31 (04): : 247 - 257
12345